To evaluate the role of inflammation in TP53-driven leukemia progression, we performed competitive mouse transplantation experiments between CD45.1+ Vav-iCre Trp53R172H/+ and CD45.2+Trp53+/+ BM cells followed by repeated poly(I:C) or lipopolysaccharide (LPS) intraperitoneal injections. Here, TP53 is linked to leukemia.